Work

A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial

Year: 2008

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Journal of Thrombosis and Thrombolysis

DOI: 10.1007/s11239-008-0230-1

Authors: David A. Morrow, Chaim M. Brickman, Sabina A. Murphy, Kenneth Baran, Ricardo Krakover, Harold Dauerman, Sujatha Kumar, Natanya Slomowitz, Laura Grip, Carolyn H. McCabe, Andrew L. Salzman

Institutions: Brigham and Women's Hospital, Thrombolysis in Myocardial Infarction Study Group, Inotek Pharmaceuticals (United States), Assaf Harofeh Medical Center, University of Vermont, University of Vermont Medical Center

Language: English

Topic: Cardiac Ischemia and Reperfusion

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Institutes of Health, National Heart, Lung, and Blood Institute

Awards: PARP inhibitor therapy for acute myocardial infarction, G948135342

OpenAlex ID: W2015720223

FWCI: 4.495

Cites: 17

Cited by: 88

Related to: 10